TLDR
- Artelo Biosciences (ARTL) surged 618% after announcing plans to explore its drug ART27.13 as a companion therapy for GLP-1 obesity treatments.
- The stock then crashed more than 23% on Monday after the company announced a $31.4 million capital raise through stock and warrant sales.
- Artelo agreed to sell approximately 3.18 million shares at $3.45 per share, raising gross proceeds of around $11 million.
- Additional warrants covering up to 6.37 million shares could bring in another $20.4 million if exercised in full.
- The private placement was priced at-the-market under Nasdaq rules and was expected to close Monday, March 30.
Artelo Biosciences stock was trading down more than 23% early Monday after the biopharma company disclosed plans to raise up to $31.4 million through a stock and warrant offering.
Artelo Biosciences, Inc., ARTL
The sell-off follows a dramatic 230.41% spike on the previous Friday, which itself came two days after Artelo announced it was exploring its experimental drug ART27.13 as a potential companion therapy for GLP-1-based obesity treatments.
The timing of the capital raise — right after such a sharp run-up — appears to have rattled investors, raising concerns about dilution.
Artelo said it entered into definitive agreements to sell approximately 3.18 million shares of common stock at a combined purchase price of $3.45 per share. That is expected to generate gross proceeds of around $11 million before fees and expenses.
The company also plans to offer warrants giving investors the right to buy up to 6.37 million additional shares. If exercised in full on a cash basis, those warrants could add roughly $20.4 million to Artelo’s coffers.
Artelo was clear, however, that there is no guarantee the warrants will be exercised. “No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants,” the company said in its statement.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The private placement is being conducted under Section 4(a)(2) of the Securities Act and Regulation D. The securities have not been registered under federal or state securities laws. Artelo has agreed to file a resale registration statement covering the securities issued.
Proceeds from the raise are earmarked for working capital, repayment of certain bridge debt, and general corporate purposes.
ART27.13 and the GLP-1 Opportunity
The original surge was driven by Artelo’s Wednesday announcement that it was exploring ART27.13 — an experimental drug targeting the body’s endocannabinoid system — as a potential companion to GLP-1 treatments.
GLP-1 drugs, which manage blood sugar and appetite, are at the centre of the fast-growing obesity market. That space is dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
Artelo said earlier research in cancer patients suggested ART27.13 may help preserve muscle mass in patients using GLP-1 drugs. The company has since filed a provisional patent covering this potential application.
“With new non-clinical research commencing and the recent filing of a patent application covering the use of CB2 agonists with GLP-1 drugs, we are aiming to build a scientific and strategic foundation with ART27.13 in an area of potentially significant commercial relevance,” said Andrew Yates, Artelo’s chief scientific officer.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
